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Major osteochondral defect (ICRS 4 > 10CM2) treated with 
autologus bone marrow mesenchymal stem cells transplanted in 
a collagen type II extracellular matrix
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Purpose: Osteochondral Defect (OD) has a poor spontaneous 
regenerative capacity. Therapy with Autologus bone marrow 
derived mesenchymal stem cells (BMMSCs) differentiated over a 3D 
membrane has not been reported in humans. Purpose: To describe 
the technique for repair OD with BMMSCs in a collagen type II Matrix 
and its clinical and radiological results. 
Methods and Materials: A 32 years old patient carrying OD ICRS>4, 
greater 10cm2 an iliac puncture was performed and bone marrow 
aspirated was collected (15 ml). MSCs were obtained by a density 
gradient and they were plated at concentration of 106 cells/ml and 
incubated at 37°C/5% CO~2~ in expansive medium. When MSCs 
BDIJFWFEPG DPO¿VFODF UIFZXFSF USJQTJOJ[BUFEBOE SFQMBUFE
over a collagen typeII matrix (20.000MSCs/cm2) at 37°C/5% 
CO~2~ in expansive medium for 14 days. 3 days before the surgical 
procedure, the expansive medium was supplemented with TGF-b1 
	 OHNM
 BOE *541SFNJY 5IF TVSHJDBM QSPDFEVSF DPOTJTUFE PO
open debridement. Subchondral bone defect was restorated with 
autologous cancellous graft and the MSCs in a collagen type II matrix 
were positioned over the top of the lesion and sutured to the to the 
rim surrounding the OD. Clinical and radiological follow up was of 6 
months. 
Results: At follow up, the patients have recovered articulate 
functionality with minimal pain and complete radiological integration 
of the scaffold. 
Conclusions: We demonstrated successfully repair of OD ICRS>4
with BMMSCs in a collagen type II matrix. We propose this technique 
as a new savage alternative in the treatment of OD ICRS>4. 
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Major osteochondral defect (ICRS 4) treated with autologus 
bone marrow mononuclear cell Fraction in a collagen type II 
extracellular matrix
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Purpose: Osteochondral Defect (OD) has a poor spontaneous 
regenerative capacity. Mesenchymal Stem Cells (MSCs), capable of 
differentiating into chondroblast and osteoblast are present in the 
bone marrow mononuclear cell fraction of human (BMMCF). Therapy 
with BMMCF could be useful in the treatment of OD. Purpose: To 
describe the technique for repair OD with BMMCF in a collagen type 
II Matrix and its clinical and radiological results. 
Methods and Materials: A 25 years old patient carrying OD ICRS 4 
an iliac puncture was performed and bone marrow aspirated was 
collected (15 ml) and BMMCF was obtained by a density gradient 
performed in the surgical room. The surgical procedure consisted 
on open debridement. Subchondral bone defect was restorated 
with autologous cancellous graft and the BMMCF was added to a 
collagen type II matrix. This matrix was positioned over the top of the 
lesion and sutured to the the rim surrounding the OD. Clinical and 
radiological follow up was of 3 months. 
Results: At follow up, the patients have recovered articulate 
functionality with minimal pain. The radiological evaluations show a 
complete integration of the scaffold. 
Conclusions: We demonstrated successfully repair of OD ICRS>4
with BMMCF in a collagen type II matrix obtained in the surgical 
room. We propose this technique as a new savage alternative in the 
treatment of OD ICRS>4. 
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The phenotype, survival, distribution, and integration of 
autologous chondrocytes used to treat articular cartilage defects 
in a rabbit model.
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Purpose: It is hypothesized that in autologous chondrocyte 
implantation (ACI) autologous chondrocytes alone contribute to 
the repair process by synthesizing components of the cartilage 
extracellular matrix (ECM). However, other cells from surrounding 
tissues also have the ability to contribute to cartilage repair, 
TQFDJ¾DBMMZ JO PTUFPDIPOESBM MFTJPOT *U SFNBJOT UP CF TFFO
in osteochondral defects whether the implanted autologous 
chondrocytes act alone or in concert with these cells to generate 
repair cartilage 
Methods and Materials: First we tested the phenotypic maintenance 
(collagen II and S-100) of these chondrocytes with passage, the 
NPSQIPMPHJDBM BOE BQPQUPUJD QSP¾MF PG UIFTF DFMMT GPMMPXJOH DFMM
labeling (PKH26) using confocal microscopy and trypan blue 
exclusion, and the distribution of the cells following seeding onto 
type I/III collagen membrane. We then tested the fate of these 
membrane-laden chondrocytes after their implantation into a rabbit 
model of osteochondral knee injury. 
Results: Results showed that the chondrocytes are phenotypically 
stable after 3 passages, with abundant type II collagen and S-100 
production. Dose-response evaluation of the effect of PKH26 on the 
chondrocytes evidenced decreasing viability as label concentration 
increased, with 10-6. TIPXJOH  WJBCJMJUZ %ZF ¿VPSFTDFODF
intensity was maximal at 10-5M, and showed a dramatic reduction in 
intensity below 10-6M. Furthermore, time-course analysis of PKH26 
labeling of the chondrocytes illustrated adequate cell labeling to 4 
weeks culture, with a gradual decline thereafter. Confocal imaging 
of the labeled chondrocytes aboard the collagen membrane showed 
an increase in cell number from day 4 to day 14, and a growth 
distribution dictated by the underlying membrane matrix. 
Conclusions: Following implantation, labeled chondrocytes were 
WJTVBMJ[FEBUUIFNFNCSBOF¾CSJOJOUFSGBDFBUGPVSEBZTXJUITPNF
cells migrating into the sealant at later time points. This study 
illustrates the feasibility of using cell surface dyes to track the fate of 
cells implanted as part of ACI 
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Giant cell tumour of bone associated with matrix-associated 
autologous chondrocyte transplantation/implantation – a case 
report
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Purpose: Giant Cell Tumour (GCT) of bone is a benign primary 
neoplasm found most commonly in the extremities of the long bones 
PGXPNFO JOUIFJSTFDPOEUP¾GUIEFDBEFTBDDPVOUJOH GPSPG
all primary bone tumours in Australia. The most common treatment 
is intralesional surgical curettage, with either cementation or bone 
grafting of the tumour bed, offering local control rates of between 
80 and 90% but there is concern this results in increased rates of 
arthritis due to increasing stiffness. We report a case of a GCT treated 
with curettage and cementation, later complicated by a defect in 
the underlying articular cartilage, successfully treated with Matrix-
associated Autologous Chondrocyte Implantation (MACI) with more 
than 2 years of follow up. 
Methods and Materials: $IPOESBMJOKVSZDPO¾SNFECZDMJOJDBMFYBN
and MRI. Arthroscopic biopsy, with MACI graft (Verigen, Australia) 
implanted 6 weeks later via open arthrotomy, and standardised 
graduated weight bearing rehabilitation. Clinical and radiological 
GPMMPX VQ GPS  ZFBST XJUI .3* JO¾MM TDPSFE JOEFQFOEBOUMZ VTJOH
validated scoring system, and progress monitored by independant 
exercise therapists using KOOS & 6 min walk test. 
Results: .3*JO¾MMDPNQPTJUFTDPSFJNQSPWFEGSPNBUNPOUIT
to 2.8/4. All components of KOOS score improved to pre injury levels 
(pain/symptoms/ADL/sport/qual life=65/82/71/25/44 at 2 years). 
6 min walk improved from 300m pre op to 450m at 2 years. 
Conclusions: Our results show that despite the hostile mechanical 
environment MACI shows promise in treating chondral defects 
in patients in non-conventional situations, where alternatives 
(osteotomy/arthroplasty) may be inappropriate. 
